secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001628280-26-022931
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics receives FDA Fast Track for CTIM-76 in platinum-resistant ovarian cancer
--------------------------------------------------------------------------------

- FDA granted Fast Track Designation for CTIM-76 (CLDN6 x CD3 bispecific antibody) in PROC after all standard therapies.
- Phase 1a trial evaluating CTIM-76 in CLDN6-positive ovarian, endometrial, and testicular cancers is ongoing.
- Interim data from the Phase 1a trial expected in June 2026.
- Fast Track aims to expedite development and review for serious conditions with unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026022931/0001628280-26-022931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026022931/cntx-20260402.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-022931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer